Cargando…
Patient-derived mesenchymal stem cells as delivery vehicles for oncolytic virotherapy: novel state-of-the-art technology
Oncolytic virotherapy is gaining interest in the clinic as a new weapon against cancer. In vivo administration of oncolytic viruses showed important limitations that decrease their effectiveness very significantly: the antiviral immune response causes the elimination of the therapeutic effect, and t...
Autores principales: | Ramírez, Manuel, García-Castro, Javier, Melen, Gustavo J, González-Murillo, África, Franco-Luzón, Lidia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918392/ https://www.ncbi.nlm.nih.gov/pubmed/27512678 http://dx.doi.org/10.2147/OV.S66010 |
Ejemplares similares
-
Genetic and Immune Changes Associated with Disease Progression under the Pressure of Oncolytic Therapy in A Neuroblastoma Outlier Patient
por: Franco-Luzón, Lidia, et al.
Publicado: (2020) -
Delivery and Biosafety of Oncolytic Virotherapy
por: Li, Lizhi, et al.
Publicado: (2020) -
ONCOLYTIC VIROTHERAPY
por: Russell, Stephen J, et al.
Publicado: (2012) -
Systemic oncolytic adenovirus delivered in mesenchymal carrier cells modulate tumor infiltrating immune cells and tumor microenvironment in mice with neuroblastoma
por: Franco-Luzón, Lidia, et al.
Publicado: (2020) -
Advances in oncolytic virotherapy
por: Russell, Stephen J., et al.
Publicado: (2022)